There and turn back again: the application of phage serine integrases in eukaryotic systems.

IF 4.3 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Frontiers in Bioengineering and Biotechnology Pub Date : 2025-02-24 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1478413

Thais Torquato Sales, Marco Antônio de Oliveira, Lilian Hasegawa Florentino, Rayane Nunes Lima, Elibio Rech

{"title":"There and turn back again: the application of phage serine integrases in eukaryotic systems.","authors":"Thais Torquato Sales, Marco Antônio de Oliveira, Lilian Hasegawa Florentino, Rayane Nunes Lima, Elibio Rech","doi":"10.3389/fbioe.2025.1478413","DOIUrl":null,"url":null,"abstract":"Serine integrases (Ints) have gained prominence and have been extensively used in Synthetic Biology due to their ability to modify DNA sequences. Ints are recombinases encoded by the phage genome and have been used to unidirectionally catalyze an insertion, excision, or inversion of a specific DNA sequence between the two attachment sites (att) attB (bacterial attachment site) and attP (phage attachment site). The entire process is highly specific and accurate; therefore, Ints are widely used in genetic engineering and have been extensively studied due to their unique site-specific recombination properties and potential genome editing applications. Furthermore, new recombinational factors (RDFs) and their determinants are constantly being discovered, underlining the need to update progress in research involving Ints in eukaryotic cells. In this way, this review aims to provide an overview of Ints in eukaryotic cells and highlight how Ints can be used in innovative ways to advance genetic engineering applications in health, agriculture, and environmental sciences.","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1478413"},"PeriodicalIF":4.3000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1478413","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Serine integrases (Ints) have gained prominence and have been extensively used in Synthetic Biology due to their ability to modify DNA sequences. Ints are recombinases encoded by the phage genome and have been used to unidirectionally catalyze an insertion, excision, or inversion of a specific DNA sequence between the two attachment sites (att) attB (bacterial attachment site) and attP (phage attachment site). The entire process is highly specific and accurate; therefore, Ints are widely used in genetic engineering and have been extensively studied due to their unique site-specific recombination properties and potential genome editing applications. Furthermore, new recombinational factors (RDFs) and their determinants are constantly being discovered, underlining the need to update progress in research involving Ints in eukaryotic cells. In this way, this review aims to provide an overview of Ints in eukaryotic cells and highlight how Ints can be used in innovative ways to advance genetic engineering applications in health, agriculture, and environmental sciences.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.